Vaxcyte (NASDAQ:PCVX) Stock: Insider Elvia Cowan Sells 19,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CAO Elvia Cowan sold 19,000 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $86.74, for a total value of $1,648,060.00. Following the completion of the sale, the chief accounting officer owned 27,860 shares of the company’s stock, valued at approximately $2,416,576.40. The trade was a 40.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte Trading Up 0.4%

PCVX stock traded up $0.26 during trading on Wednesday, reaching $66.96. 11,559,439 shares of the stock were exchanged, compared to its average volume of 1,556,494. The firm has a market capitalization of $9.96 billion, a price-to-earnings ratio of -8.78 and a beta of 1.23. The business has a 50 day moving average price of $59.28 and a 200-day moving average price of $56.40. Vaxcyte, Inc. has a 1 year low of $39.87 and a 1 year high of $90.75.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the previous year, the business posted ($1.22) EPS. On average, research analysts anticipate that Vaxcyte, Inc. will post -8.07 EPS for the current year.

Institutional Trading of Vaxcyte

Several hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC boosted its holdings in Vaxcyte by 4.0% during the second quarter. Hsbc Holdings PLC now owns 4,151 shares of the company’s stock worth $241,000 after buying an additional 159 shares in the last quarter. Meeder Advisory Services Inc. increased its stake in Vaxcyte by 2.9% in the 1st quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after purchasing an additional 231 shares in the last quarter. IFP Advisors Inc boosted its position in Vaxcyte by 72.8% during the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after purchasing an additional 236 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Vaxcyte by 27.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,344 shares of the company’s stock valued at $78,000 after purchasing an additional 291 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Vaxcyte by 7.0% in the first quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock valued at $307,000 after buying an additional 343 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PCVX shares. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. BTIG Research restated a “buy” rating and issued a $89.00 price objective on shares of Vaxcyte in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday. Bank of America lowered their target price on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research note on Monday, September 28th. Finally, Guggenheim lifted their price target on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $108.60.

Trending Headlines about Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Vaxcyte’s VAX-31 candidate delivered a positive Phase 3 result in the adult pneumococcal vaccine market. The late-stage win strengthens the case for VAX-31 and was viewed by some analysts as a potentially best-case outcome, improving confidence in the company’s path toward commercialization. Vaxcyte leaps on positive Phase III trial of VAX-31
• Positive Sentiment: Analyst support remains favorable. BTIG reaffirmed a Buy rating, while Needham assigned a $122 price target, substantially above recent trading levels. Additional VAX-31 data and other pipeline readouts are expected in the first half of 2027, providing potential future catalysts. BTIG Research Reaffirms Buy Rating for Vaxcyte
• Neutral Sentiment: Vaxcyte priced concurrent offerings totaling approximately $1 billion: about $500 million through common stock and pre-funded warrants at roughly $64 per share, plus $500 million of 1.50% convertible senior notes due 2032. The company can also sell additional securities underwriters’ over-allotment options. Proceeds should strengthen its balance sheet and fund VAX-31 development, manufacturing and other pipeline programs. Vaxcyte Announces Pricing of Concurrent Public Offerings
• Negative Sentiment: The equity component creates near-term dilution, while the convertible notes introduce potential future dilution if converted. The financing announcement overshadowed some of the clinical optimism and prompted a sharp retreat from the stock’s recent highs.
• Negative Sentiment: Unusually high put-option activity—8,093 contracts, reportedly 259% above typical volume—suggests increased hedging or bearish speculation, although options activity alone does not establish a fundamental change in Vaxcyte’s outlook.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.